抗肥胖藥的全球市場 2023

Anti-Obesity Drugs

出版日期: 2023年03月01日 | 出版商:

Global Industry Analysts, Inc. | 英文 264 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

抗肥胖藥的全球市場到2030年將達到48億美元

在COVID-19後改變的商務環境中，2022年25億美元的抗肥胖藥的全球市場到2030年將達到48億美元，在2022年～2030年間預計將以年複合成長率8.4％的速度成長。本報告所分析的市場區隔之一的處方箋醫藥品，年複合成長率將記錄8.1％，到分析期間結束時達到44億美元。考慮疫情後的復甦，成藥市場區隔今後8年的年複合成長率將修正為11.1％。

美國市場估算為7億5,040萬美元，中國則將以年複合成長率7.5％增長

美國的抗肥胖藥市場在2022年估算為7億5,040萬美元。作為世界第2大經濟大國的中國，在2022年～2030年間預計將以年複合成長率7.5％推移，2030年達到8億1,220萬美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年～2030年間預計將各以7.4％和6.4％的速度成長。在歐洲市場中，德國以年複合成長率約6.3％成長。

調查對像企業範例

Eisai Co. Ltd.(Japan)
F. Hoffmann-La Roche Ltd.(Switzerland)
GlaxoSmithKline Plc
Novo Nordisk A/S(Denmark)
Rhythm Pharmaceuticals(US)
VIVUS Inc.(US)

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Anti-Obesity Drugs Market to Reach $4.8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Anti-Obesity Drugs estimated at US$2.5 Billion in the year 2022, is projected to reach a revised size of US$4.8 Billion by 2030, growing at aCAGR of 8.4% over the period 2022-2030. Prescription Drugs, one of the segments analyzed in the report, is projected to record 8.1% CAGR and reach US$4.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the OTC Drugs segment is readjusted to a revised 11.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $750.4 Million, While China is Forecast to Grow at 7.5% CAGR

The Anti-Obesity Drugs market in the U.S. is estimated at US$750.4 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$812.2 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.4% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.

Select Competitors (Total 23 Featured):

Eisai Co. Ltd. (Japan)
F. Hoffmann-La Roche Ltd. (Switzerland)
GlaxoSmithKline Plc
Novo Nordisk A/S (Denmark)
Rhythm Pharmaceuticals (US)
VIVUS Inc. (US)

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Obesity and Overweight Statistics
- Recent Market Activity
- Obesity - A Prelude
- Anti-Obesity Drugs: A Market Characterized by High Unmet Needs
- Currently Available Anti-Obesity Medications
- Select Currently Available Short-term and Long-term Anti-Obesity Medication
- Select Off-Label Drugs for Obesity
- Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus to Market Growth
- Semaglutide: Highest Potential in the AOM Pipeline
- Setbacks of Past Drugs
- Positive Road Ahead for Belviq
- Relaunch of Xenical
- Relaunch of Contrave®
- Reluctance among Patients, Physicians, and Payers Hurts Market Prospects
- New Drug Development - High on the Agenda, Despite the Market Restraints
- Anti-Obesity Drugs in Phase-III Clinical Trials: As of July 2018
- Anti-Obesity Drugs in Phase-II Clinical Trials: As of July 2018
- Anti-Obesity Drugs in Phase-I Clinical Trials: As of July 2018
- Diabetes Drug Companies Attempt to Foray into the Anti-Obesity Drugs Space
- Competitive Landscape
- Novo Nordisk - The Leading Player in the Market
- The United States - The Largest Obesity and Anti-Obesity Market
- Europe - A Market with Vast Potential
- Obesity Creeps Up in Developing Countries
- Anti-Obesity Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
- F. Hoffmann-La Roche Ltd. (Switzerland)
- GlaxoSmithKline Plc. (UK)
- Eisai Co., Ltd. (Japan)
- Novo Nordisk A/S (Denmark)
- Rhythm Pharmaceuticals (USA)
- VIVUS, Inc. (USA)
3. MARKET TRENDS & DRIVERS
- Alarming Rise in Global Obesity Levels - The Major Growth Factor
- Classification of BMI
- Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion
- Growing Middle Class Population to Drive the Market Growth
- Childhood Obesity - A Market with Unmet Needs
- Commercial Weight-Loss Companies Foray into the Market
- Online Drug Stores Boost Sales
- Barriers to Development of Effective Drugs
- Regulatory Additions - A Barrier to Entry?
- High Drug Development Costs - A Major Setback
- Weight Loss Alternatives - A Market Dampener
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 2: World 8-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
- TABLE 3: World Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 4: World 8-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for OTC Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 6: World 8-Year Perspective for OTC Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- TABLE 7: World Anti-Obesity Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
- Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- TABLE 8: USA Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 9: USA 8-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2023 & 2030
CANADA
- TABLE 10: Canada Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 11: Canada 8-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2023 & 2030
JAPAN
- Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- TABLE 12: Japan Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 13: Japan 8-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2023 & 2030
CHINA
- Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- TABLE 14: China Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 15: China 8-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2023 & 2030
EUROPE
- Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- TABLE 16: Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 17: Europe 8-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
- TABLE 18: Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 19: Europe 8-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2023 & 2030
FRANCE
- Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- TABLE 20: France Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 21: France 8-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2023 & 2030
GERMANY
- Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- TABLE 22: Germany Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 23: Germany 8-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2023 & 2030
ITALY
- TABLE 24: Italy Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 25: Italy 8-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2023 & 2030
UNITED KINGDOM
- Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- TABLE 26: UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 27: UK 8-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2023 & 2030
REST OF EUROPE
- TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 29: Rest of Europe 8-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2023 & 2030
ASIA-PACIFIC
- Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 31: Asia-Pacific 8-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2023 & 2030
REST OF WORLD
- TABLE 32: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 33: Rest of World 8-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2023 & 2030